Changes in Cost of Guideline-Concordant Cancer Treatment: Observations and Implications
This study observed an increase in absolute median cost of cancer therapy on a treatment indications level, largely driven by new biomarker-driven indications and therapies.
Authors
- Aaron Philip Mitchell (ORCID: https://orcid.org/0000-0003-3639-3515)
- Nirjhar Chakraborty (ORCID: https://orcid.org/0009-0003-8104-4311)
- Pranam Dey
- Judy J. Wang (ORCID: https://orcid.org/0000-0003-4905-6593)
- Sara Tabatabai (ORCID: https://orcid.org/0000-0002-5498-7176)
- Sonia Persaud (ORCID: https://orcid.org/0009-0008-5666-7994)
- Niti U. Trivedi (ORCID: https://orcid.org/0000-0002-3967-6492)
Institutions
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- University of Chicago (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1200/op-24-00995
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00